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Summary Deletions of tumour-suppressor genes can be detected by loss of heterozygosity (LOH) studies, which were performed on 23
cases of adenocarcinoma of the oesophagus, using 120 microsatellite prmers coverng all non-acrocentric autosomal chromosome arms.
The chromosomal arms most frequently demonstrating LOH were 3p (644% of tumours). 5q (45%), 9p (52%), lip (61%), 13q (500°), 17p
(96%). 1 7q (55%) and 18q (70o). LOH on 3p, 9p, 13q, 17p and 18q occurred mainly within the loci of the VHL, CDKN2. Rb, TP53 and DCC
tumour-suppressor genes respectively. LOH on 5q occurred at the sites of the MSH3 mismatch repair gene and the APCtumour-suppressor
gene. 11p15.5 and 17q25-qter represented areas of greatest LOH on chromosomes 11p and 17q, and are putative sites of novel tumour-
suppressor genes. LOH on 9p was significantty associated with LOH on 5q, and tumours demonstrating LOH at both the CDKN2(9p21) and
MSH3 (5q11-q12) genes had a significantly higher fractional allele loss than those retaining heterozygosity at these sites. Six of nine
carcinomas displaying microsatellite alterations also demonstrated LOH at CDKN2, which may be associated with widespread genomic
instability. Overall, there are nine sites of LOH associated with oesophageal adenocarcinoma.
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The incidence ofadenocarcinoma ofthe oesophagus has increased
at a greater rate than anx other tumour over the last 20 Xears (Blot
et al. 1991). and is nou the most common oesophaaeal malig-
nancy in certain parts of the Western world (Spechler et al. 1994).
The reason for this increase is not clear. Howexer. it is knou-n that
Barrett's oesophagrus. uwhich occurs in approximatelv 10% of
patients with gastro-oesophageal reflux. is associated with a
30-125 times increased risk of developing adenocarcinoma
(Spechler et al. 1984: Cameron et al. 1985: W-illiamson et al.
1991). It is estimated that approximately 1% of patients with
Barrett's oesophagrus will develop adenocarcinoma each x-ear. and
this can occur up to 20 Xears after the initial diarnosis of Barrett's
oesophagus (Spechler. 1987). The histological progression
durinc this period is considered to follou- metaplasia-low-grade
dNsplasia-high-grade dvsplasia-carcinoma (IMiros et al. 1991).
High-grade dysplasia (HGD) has been used as a mark-er of future
cancer development. but there is interobserxer variation in the
diagynosis ofHGD (Reid et al. 1988) and not all patients with HGD
A ill dexvelop cancer (Schnell et al. 1996).
Attention has therefore focused on molecular biomarkers of
carcinogenesis. Loss of function of tumour-suppressor genes
resultinc from genormic insults has been implicated in the develop-
ment of several different tumours. and these loss offunction muta-
tions ma!- be detected bv loss of heterozx7gosit- (LOH) studies
(Ittman and W'ieczorek. 1996: Shimizu and Sakiva. 1996). LOH
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studies can lead to the identification of tumour-suppressor genes
that are inactix ated in the metaplasia-dxsplasia-carcinoma
progression. and may therefore be useful as biomarkers of future
carcinogenesis in patients w-ith Barrett's metaplasia and dxsplasia
undergoing endoscopic surveillance.
Previous alleleotype analx ses have detected LOH in more than
40%c of oesophageal adenocarcinomas on chromosome arms lp.
4q. 5q. 9p. 13q. 17p and 18q (Barrett et al. 1996a and Hammoud et
al. 1996). These allelotype studies AWere undertak-en Awith 43 and 39
microsatellite primers respectixely. We have performed the most
comprehensive genomic study of oesophageal adenocarcinoma to
date. coxering all of the non-acrocentnrc chromosome arms w-ith
120 microsatellite pnrmers. enabling identification of putatiVe
tumour-suppressor gene sites in oesophageal adenocarcinoma.
MATERIALS AND METHODS
Patients
Twentv-three cases of adenocarcinoma of the oesophagus diag-
nosed betmeen 1992 and 1996 were studied. Twenty of these
patients were male and their mean age xxas 68 y-ears. At present.
six ofthese patients are alix e with no signs ofrecurrent disease.
DNA extraction
Tissue from the tumour and from normal gastric mucosa were
obtained from endoscopic biopsies and from surgical resections.
snapped frozen in liquid nitroaen and stored at -70 C. Areas of
tumour containincg minimal stromal cells wxere microdissected and
DNA extracted from the microdissected tissues usinc the Nucleon
II extraction kit (Scotlab).
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PCR and LOH analysis
A total of 120 microsatellite primers representing 39 autosomal
chromosomal arms % ere used to studv the genome ofeach tumour
(Table 1). the emphasis on chromosome arms that harbour know-n
tumour-suppressor genes or in which a high degree of LOH has
been detected in other tumours. Howexver. at least one microsatel-
lite primer wvas studied for each non-acrocentnrc chromosome
arm. A 25-gl PCR mixture containing 100 ng of extracted DNA.
S pmol of foru-ard and reverse DNA primers. 200g-'d of dN`TP.
0.5 units of Taq pol-merase. and 2.5 il of standard ammonia
buffer containing 1.5 11 of 1.5 mrr magnesium chloride (Bioline)
was used in the following reaction: 953C for 5 min. then 30 cycles
of 94 C for 30 s. 55-59 C for 30 s (depending on the primer) and
72-C for 1 min. follow-ed bv 72-C for 5 min.
An aliquot of 10 g1 of the PCR product w-as electrophoresed
overnight on a 10%c polvacrxlamide gel. and the results visualized
by sil er staining. There are three possible results for each primer
used: heterozygous patients have both alleles present in tumour
and normal tissue. homozygous patients has-e a single corre-
sponding allele in both tumour and normal tissue and LOH is indi-
cated by the absence. or a greater than 50% reduction in intensitv.
of an allele in the tumour tissue (Figure 1). Homozvoous patients
are regarded as non-informatixe at that locus. LOH was taken to
indicate the site of a putative tumour-suppressor gene. However. it
has been noted that certain PCR techniques cannot distincuish
betw-een allelic duplication or low-level amplification leading to
LOH (Ah-See et al. 1994). This suggests that LOH may not
always be indicatixe of the presence of a tumour-suppressor gene.
and confirmation that a site of LOH contains a tumour-suppressor
gene requires mutational analy sis.
Microsatellite alterations
The microsatellite primers used to study LOH can also detect
microsatellite alterations. w-hich are indicated by a shift in the
electrophoretic band of the tumour tissue relative to the band of
normal tissue. Seventxv-four of the 120 primers used in the LOH
analy sis W-ere used to study microsatellite alterations.
Fractional allele loss
The fractional allele loss (FAL) w-as calculated for each tumour as
the number of chromosomal arms demonstratinr LOH divided bv
the number of informatix e chromosomal arms.
Statistical analysis
Comparison ofthe clinicopathological parameters and FAL values
of the tumours w-as performed by the Fisher exact test. and the
Pearson correlation coefficient used to analyse the possible rela-
tionships between LOH on different chromosomal arms. Survival
>-as anal-sed by the Kaplan-Meier method and by log-rank
testine,.
RESULTS
A total of 120 microsatellite primers (Table l x were used to studx
allelic imbalance in 23 cases of oesophageal adenocarcinoma.
Each tumour demonstrated LOH w-ith at least three different
primers. and one tumour demonstrated LOH with 27 pnrmers. One
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Figure 1 LOH in tumours P02 (D17S799). PlO (D18S70). PlO (D3S1215).
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Figure 2 lndivdual allelotypes of 23 cases of oesophageal
adenocarcinoma.M. LOH: retention of heterozygosity: and the remaining
blank areas are non-informative at that locus. FAL is displayed for each
tumour. , p: q
hundred of the 120 primers used (84%S-) demonstrated LOH in at
least one tumour. and LOH Aas detected in 36 ofthe 39 autosomal
chromosome arms studied (Figure 2).
Percentage LOH on each chromosomal arm
The percentage of tumours display ing LOH was calculated for
each chromosomal arm (Table 1 and Firure 3). Eight chromo-
somal arms displayed LOH in at least 45% of the tumours: 3p
(64%c). Sq (45%7c). 9p (52%7c). lip (61c,%c). 13q (50%7). 17p (96%e).
17q (55%). and 18q (70%/ ). LOH on these chromosomal arms w-as
significantly greater than LOH detected on other chromosomal
arms (P < 0.02. Fisher's exact test). Nineteen of 23 tumours
demonstrated LOH in at least half of these chromosomal arms.
Excluding the eight chromosomal arms w-ith LOH in more than
45'%- of tumours. the background LOH was 15%. xwhich is similar
to that prexiously reported in oesophageal carcinoma (Wagata et
al. 1991: Huang et al. 1992: Bovnton et al. 1992). Allelic loss w-as
detected in only one of the p or q chromosomal arms in 78%- of
chromosomes. indicating that the majority ofdeletions represented
subchromosomal events.
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Table 1 LOH analysis of 23 oesophageal adenocarcinomas using 120mriosatellite pnmers
Chromosome LOHAnforH_atve Total LOH on
arm Primer Site cases (%) each arm (%)
1p
lq
2p
2p
3p
3q
4p
4q
5p
5q
6p
6p, 6q
6q
7p
7q
8p
8q
9p
DlSi59
DlS53
D2S207
TPO
D2S104
D3S1079
D3S659
D3S1235
D3S1211
THRBS
D3S1293
D3S656
D3S587
D3S1215
HOX7
D4S392
D5S117
D5S392
D5S118
DSSlO7
D5S346
D5S404
D5S421
IL9
D5S209
D6S470
TRM1
D6S305
D7S531
D7S473
D7S550
D8S57
ANK1
D8S261
D8S164
D9S200
D9S104
D9S161
D9S171
D9S162
D9S157
D9S156
D9S199
D9S51
D9S103
D9S67
D10S249
Dl0S212
D11S554
WT1
D1 S865
D11S419
D1 S875
TH
HRAS
DRD2
D12S61
D12S94
D12S63
D12S43
D13S217
D13S157
D13S220
D13S175
D13S168
Rb
D13S166
D13S71
D14S47
9q
1Op
1Oq
lip
llq
12p
12q
13q
14q
1p22.3-p21
1q31-q32
2p25-p23
2p25-p24
2q33-q37
3p13
3p13
3p21.3-p21 2
3p22
3p24
3p25-p24.2
3p25.1
3p26-p24
3q12
4p16.3-p16.1
4q12-q13
5,p15.3-p15.1
5p15.3-pter
5qcen-qll.2
5q11 2-q13.3
5q21-q22
5q23.3
5q23.3
5q22.9-q32.1
5q31.3-q33.3
6p25
6p23-q12
6q
7p22-ter
7q
7q31-qter
8p12
8p21.1-p11.2
8p23-p11
8q133-q22.1
9p21-p12
9p21
9p21.1-p21 .3
9p21 .3-p21 .1
9p23-p22
9p23-p22.1
9p23.3-p22.1
9p23.3-p23.1
9p22.3-p33
9qS3-qter
9q34-qter
lop
1Oqter
11p12-p1l
11p13
11p13-p14
11p15.4-p13
11p15.4-pl3
11p15.5
11p15.5
11q23.1
12p
12pter-p13.2
12qter
12q12f-q24.1
13q12
13q13
13q13
13q11-q13
13q11-q22
13q14.1-q14.2
13q21
13q32
14q11 -2-q22
0/10 (0)
1/16 (6)
0/10 (0)
2/13 (15)
1/17 (6)
3/9 (33)
2/12 (17)
0/6 (0)
3/10 (30)
0/2 (0)
0/12 (0)
315 (20)
9/16 (56)
3/19 (16)
2/10 (20)
3/16 (19)
3/11 (27)
5/17 (29)
2/13 (15)
8/17 (47)
6/18 (33)
2/15 (13)
3/15 (20)
4/12 (33)
2/10 (20)
3/18 (17)
1/6 (17)
1/12 (8)
1/13 (8)
0/13 (0)
1/11 (9)
1/12 (8)
2/11 (18)
2/18 (11)
1/15 (7)
1/11 (9)
1/10 (10)
2/11 (18)
8/16 (50)
1/13 (8)
4/19 (21)
3t9 (33)
0/6 (0)
0/13 (0)
3/10 (30)
3/11 (27)
2/11 (18)
1/11 (9)
2/13 (15)
0/13 (0)
2/16 (13)
3/7 (43)
3/13 (23)
3/12 (25)
6/16 (38)
4116 (25)
1/15 (7)
4/12 (33)
1/6 (17)
1/8 (43)
3/13 (23)
1/9 (11)
6/17 (35)
3/12 (25)
4/13 (30)
5/16 (31)
0/11 (0)
0/12 (0)
3/13 (23)
0/10 (0)
1/16 (6)
2/17 (12)
1/17 (6)
1422(64)
3/19 (16)
2/10 (20)
3/16 (19)
8&20 (40)
1am2 (45)
3/18 (17)
1/12 (8)
1/13 (8)
1/15 (7)
5/21 (24)
1/15 (7)
12123 (52)
5/16 (31)
2/11 (18)
1/11 (9)
14/23 (61)
4/16 (25)
5/19 (26)
2/9 (22)
11i22 (50)
3/15 (20)
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Table 1 cont
Chromosom LOMefornative Toal LOH on
arm Primr She cam (%) each arm(%)
15q
16p
16q
17p
17q
D14S51
CYP19
D15S87
HBAP1
D16S303
D17S935
D17S959
TCF2
D17S261
D17S842
D17S58
CHRNB1
D17S953
D17S122
D17S805
D17S520
TP53
D17S740
D17S799
D17S922
D17S955
D17S839
D17S921
D17S578
D17S783
D17S798
D17S841
D17S250
THRAl
MPO
GP3A
D17S940
D17S515
AFMcOO8we
D17S801
D17S928
D18S52
D18S59
D18S43
D18S34
DCC
D18S35
D1838
D18S42
D18S70
D19S20
D19S180
D20S57
D20S120
D21S156
IL-2RB
18p
18q
19p
19q
20p
20q
21q
22q
14q32.1-q322
15q21.1
15q25-qter
16p13.3
16p24.3
17p11.1
17p11.1
17p11.1-p12
17p11.1-p12
17p11 2
17p11 2
17p12-11.1
17p12-11.2
17p12-pll2
17p12
17p13-p12
17p13.1
17p13.1
17p13.1-p12
17p13.1-p12
17p13.1-p12
17p13.1-p12
17p13.1-p12
17p13.3-qll 2
17q11.2
17q11.2
17q112
17q11.2-q12
17q11.1-q12
17q21.3-q22
17q21.32
17q23
17q23-q25
17q24
17q25
17q25-qter
18pter-p1.2
18pter-pll .2
18q
18q12.2-q12.3
18q21.1
18q21 .1-q21.3
18q21.31
18q22.1
18q23-qter
19p13.3
19q13.4
20p13
20q13.3
21q22.3
22q13
0/9 (0)
1/13 (8)
3/13 (23)
3/17 (18)
1/11 (9)
3/5 (60)
5/12 (42)
10/17 (59)
6/14 (43)
5/10 (50)
5/6 (83)
5/11 (45)
1/6 (17)
3/12 (25)
8/16 (50)
9/19 (47)
8/17 (47)
2/7 (29)
7/12 (59)
3/8 (38)
1/6 (16)
1/11 (9)
1/10 (10)
2/8 (25)
0/9 (0)
3/18 (17)
0/7 (0)
3/16 (19)
2/18 (11)
1/8 (13)
3/12 (25)
0/4 (0)
0/9 (0)
2/7 (17)
1/4 (25)
5/20 (25)
2/11 (18)
4/15 (27)
0/8 (0)
5/17 (29)
4/13 (30)
5/16 (31)
3/10 (30)
0/8 (0)
6/17 (35)
1/10 (10)
0/17 (0)
0/18 (0)
2/20 (10)
2/11 (18)
17 (14)
4/19 (21)
3/17 (18)
1/11 (9)
22f23(96)
1222(55)
6/19 (32)
16WJ23 (70)
1/10 (10)
0/17 (0)
0/18 (0)
2/20 (10)
2/11 (18)
1/7 (14)
Percentage LOH at specific sites
The chromosomal arms previously identified as demonstrating
high LOH in other tumours were examined using at least seven
primers (range 7-19).
Fifty-four per cent of Barrett's adenocarcinomas demonstrated
LOH at 3p26-p24 (D3S587). which spans the site of the von
Hippel-Lindau (VHL) tumour-suppressor gene. LOH on chromo-
some Sq mainly occurred at two sites: half of oesophageal adeno-
carcinomas demonstrated LOH at Sqll.2-q13.3 (D5S107), which
encompasses the site ofMSH3, a DNA mismatch repair gene, and
one-third were found to have LOH at Sq21-q22 (D5S346), the site
of the adenomatous polyposis coli (APC) tumour-suppressor gene.
The D9S171 (9p21.3-p21.1) primer identified LOH in 8 of 16
informative cases. 9p21.3-p21.1 spans the site ofthe cyclin-depen-
dent kinase inhibitor 2A and 2B (CDKNV2) tumour-suppressor
genes. LOH on chromosome arm 9p was significantly correlated
with LOH on Sq (P = 0.008, Pearson correlation coefficient) and
LOH on 18q (P = 0.015, Pearson correlation coefficient). Fourteen
of 23 cases ofoesophageal adenocarcinoma had LOH detected on
chromosome arm llp. with halfofthese cases demonstrating LOH
at llpl5.5, the siteoftheH-ras oncogene. LOH on 13q occurred in
8 of 16 tumours and the site of greatest LOH on 13q was at the
retinoblastoma (Rb) locus (30%). The most common site of LOH
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Table 2 Comparison of three allelotype analyses of adenocarcinoma of the
oesophagus
No. of primers used LOH (%)
Chromosom Dolan Barrett Hammoud Dolan Barrett Hammoud
1p 1 1 1 0 41 20
3p 8 1 1 64 33 26
4q 1 1 1 19 16 54
5q 7 1 1 45 80 18
9p 9 1 1 52 64 27
lip 7 1 1 61 17 5
13q 8 2 1 50 43 15
17p 19 2 1 96 100 63
17q 13 1 1 55 24 25
18q 7 2 1 67 43 40
Tumournumber 211125200816070506 221218 13 1003 2304240102261417
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Figure 3 Percentage of tumours demonstrating loss of heterozygosity in
each chromosomal arm.
was on chromosome arm 17p. where 22 of 23 adenocarcinomas
demonstrated LOH. LOH was detected in 10 of 17 informative
tumours (59%7c) with the TCF2 primer ( I7pI 1.I-p12. and in 8 of 17
tumours (47%7) w-ith the TP53 primer (17pl3.1). the site of the
TP53 tumour-suppressor gene. LOH on 17q occurred in 55% of
tumours (12 of 22 cases). and was alwavs associated w-ith LOH
on 17p. Fiv-e of 20 tumours demonstrated LOH on 17q25-qter
(D17S928). The deleted in colon cancer (DCC) tumour-suppressor
gene is located at 18q21.1. and LOH using the DCC microsatellite
primer was detected in 4 of 13 (31%7c) oesophageal adenocarci-
nomas. LOH was also detected in 5 of 16 cases (31%7c) at
18q21. l-q2 1.3 (D18S35).
Microsatellite alterations
Nine of 23 cases (39%7c) of oesophageal adenocarcinoma demon-
strated microsatellite alterations with 13 different microsatellite
primers from a total of 70 primers studied. How-ever. only two
cases displaved microsatellite alterations "ith more than tx%-o
primers. Seven of nine cases with microsatellite alterations also
demonstrated LOH on chromosome arm 9p (P = 0.048. Fisher
exact test). and six cases demonstrated LOH at 9p21. the site ofthe
CDKN tumour-suppressor genes. Interestingly. only two cases
displaying microsatellite alterations also demonstrated LOH at
5qll.l-ql3.3 (D5S107). the site of the mismatch repair gene
MSH3.
FAL
FAL w-as calculated for each tumour as the number of chromo-
somal arms displaying LOH diNided bv the number of informatiVe
chromosomal arms. and it reflects the quantity of genetic abnor-
mality in each tumour. The median FAL was 0.30 and the mean
FAL was 0.29. indicating that on average each tumour demon-
strated LOH on 29% of its chromosomal arms. FAL %vas not
significantly related to survxval. TNM classification or grade of
tumour. However. it is of note that tumours displaying LOH at the
sites of the CDKN2 and MSH3 aenes had significantly higher
FAL values than tumours retaininga heterozy osity at these sites
(P = 0.003 and P = 0.015 respectively. Fisher's exact test).
Survival
Survival was not sionificantl1 affected bv the FAL ofeach tumour.
nor by LOH on individual chromosomes.
DISCUSSION
This represents the most in-depth study to date ofallelic imbalance
in oesophaggeal adenocarcinoma. In 23 cases of oesophageal
adenocarcinoma. LOH on chromosomes 3p. 5q. 9p. llp. 13q. 17p.
17q and 18q s as significantly greater than LOH on other chromo-
somes. The majonrty of LOH (78%c) was detected in only one of
the p or q arms for each chromosome. suggesting that subchromo-
somal events are mainly responsible for LOH.
A previous allelotype analysis of adenocarcinoma of the
oesophagus found sigonificant LOH on chromosome arms Sq. 9p.
13q and 17p (Barrett et al. 1996a). which is in agreement with this
study (Table 2). Although a previous studv has documented LOH
on chromosome 4q in more than 50%c of oesophageal adenocarci-
nomas (Hammoud et al. 1996). both our own and Barrett's allelo-
type study reported that fever than 20c of adenocarcinomas
demonstrated LOH on 4q. We also detected significant LOH on
chromosome arms 3p. 11p. 17q and 18q in our study. most prob-
ably due to the use of a greater number of microsatellite primers
for each chromosomal arm in our studv. In our study. microdissec-
tion was used to minimize stromal cell contamination of the
r tumour DNA. and this may also have contributed to ourhigh LOH
findings. Other investigators have used flow cytometrv to separate
aneuploid cells for use in LOH studies (Barrett et al. 1996a).
although not all oesophageal carcinomas exhibit aneuploidy on
DNA analysis (Dorman et al. 1992: Porschen et al. 1993: Blount
et al. 1994) and the sensitivity and specificity of the detection of
aneuploidy by flow cytometry is only 79% and 60%7 respectively
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(Walsh et al. 1992). Hence. not all oesophageal carcinomas will be
amenable to this method of tumour cell procurement.
Chromosome 3
LOH on 3p has been detected in a Xariety of tumours. e.g.
pulmonary (Sozzi et al. 1996). gastrointestinal (Ohta et al. 1996)
and ovanian (Chuaqui et al. 1996). and in our study ofoesophageal
adenocarcinoma 64%' of tumours displayed LOH. The reaion of
greatest LOH on 3p was at 3p26-p24 (primer D3S587). wxhich
contains the VHL tumour-suppressor gene locus. A previous study
failed to shoxx anv involvement of the VHL tumour-suppressor
gene in squamous cell carcinoma of the upper aerodigestive tract
(Waber et al. 1996). but allelic loss of the VHL gene has been
described in sporadic colon cancer (Zhuang et al. 1996) and
sporadic renal cell carcinomas (Van den Berg et al. 1996). LOH at
3p25 has been shown to be associated xxith lymph node metastases
in squamous cell carcinoma of the oesophagus (Ogasawara et al.
1995): 7 of 13 Barrettfs adenocarcinomas displayed LOH at
3p26-p24 in this study. and six of these sexven tumours had posi-
tixe nodes. It is likely that 3p26-p24 contains a tumour-suppressor
uene in olved in oesophageal carcinogenesis. but whether it is the
1'HL tumour-suppressor gene or anearby novel tumour-suppressor
2ene remains to be determined.
Chromosome 5
LOH on chromosome arm 5q wxas detected in 9 of 20 cases (45%)
of oesophageal adenocarcinoma. and this LOH w-as concentrated
in two sites. One-third oftumours demonstrated LOH at 5q2I-q2_2
(D5S346). the site oftheAPCtumour-suppressor gene. LOH at the
APC tumour-suppressor gene has previously been described in 23
of 61 cases (38%7,) of squamous cell carcinoma of the oesophagus
(Ogasawara et al. 1996). Howxexer. single-strand conformation
polxmorphism analysis found only one APC mutation in 35 cases
of oesophaaeal squamous cell carcinoma. and one APC mutation
in 18 cases of oesophageal adenocarcinoma (Powell et al. 1994).
Hence the role. if any. of the APC tumour-suppressor gene
in oesophageal adenocarcinoma is yet to be determined.
Sql1.2-q13.3 (D5S107) represented the site of greatest LOH on
chromosome 5q. with 8 of 17 oesophageal adenocarcinomas
demonstrating LOH. MSH3. a mismatch repair gene. has been
mapped to 5ql l-q12. and may be the target of LOH detected by
D5S107 in oesophageal adenocarcinoma. Of the eirht tumours
demonstrating LOH at this site. two also displayed microsatellite
alterations with other primers.
Chromosome 9
Eiaht of 16 tumours displayed LOH at 9p2I.3-p21.1 (D9S171 ). and
LOH at this site has previously been detected in 24 of32 adenocar-
cinomas of the oesophagus (Barrett et al. 1996b). DNA sequencing
has detected mutations in the CDKN2 tumour-suppressor genes in
both adenocarcinoma and squamous cell carcinoma of the oesoph-
agus (Zhou et al. 1994: Barrett et al. 1996b). The target of LOH at
9p21.3-21.1 is most likelx to be the CDKN2 tumour-suppressor
genes. but confirmatorx mutational analysis is required. Three of23
cases of oesophageal adenocarcinoma in our study A-ere classified
as T1 NO MO. and txo of these tumours demonstrated LOH at the
site of the CDKN2 tumour-suppressor genes. Hence. allelic loss at
the site of the CDKN2 tumour-suppressor genes is a frequent and
perhaps early e-ent in oesophageal carcinogenesis. and deserves
further study as a potential markerofcarcinogenesis in patients with
Barrett's oesophagus.
Chromosome 11
The HRASJ primer wxas used to detect 38%/- LOH at lIpl5.5 in
oesophageal adenocarcinoma. and has previously been used to
demonstrate LOH in 40%'7 of squamous cell carcinomas of the
oesophagus (Shibagaki et al. 1994). LOH at I Ip15.5 has also been
demonstrated in adenocarcinoma of the stomach (Baffa et al.
1996). and candidate tumour-suppressor grenes in this regrion
include 117 andHI9. loss ofw-hich have been described in 'ilms'
tumours (Besnard-Guerin et al. 1996) and in cervical cancer (Douc-
Rasy et al. 1996) respectively. This area on 1 lp obviously requires
further study in oesophageal and other malignancies.
Chromosome 13
LOH at the Rb locus was detected in 5 of 16 cases (31c%) of
oesophageal adenocarcinoma. which is similar to the 36%;-e LOH
detected in a prexvious studx of 14 cases of oesophageal adeno-
carcinoma (Boxnton et al. 1991).
Chromosome 17
Twxentyv-twxo of 23 oesophageal adenocarcinomas had LOH
detected on chromosome 17p. and 8 of 17 tumours demonstrated
LOH at the site of the TP53 tumour-suppressor gene (TP53
primer). Previous studies have detected LOH on chromosome 17p
in 14 of 14 (Neshat et al. 1994). 30 of 31 (Blount et al. 1994) and
11 of 16 (Gleeson et al. 1995) oesophageal adenocarcinomas. Two
of three intramucosal adenocarcinomas (TI NO MO) in our studv
demonstrated LOH at the site of the TP53 tumour-suppressor
gene. suagesting that LOH at this site is an earlv exvent in
oesophageal carcinogenesis. Similarly. TP53 mutations haxe been
detected in HGD adjacent to adenocarcinomas (Hamelin et al.
1994: Gleeson et al. 1995). The TP53 gene merits further studv as
a marker of carcinogenesis in patients with Barrett's oesophagrus.
LOH was detected in 59% ofinformative tumours wxith the TCF-2
primer and in 43%c of tumours with D17S261. markers at
l7p 1-.I-p12. indicatincg the presence of a putatixe tumour-
suppressor gene. originally reported by Swift et al (1995).
BRCAI is a tumour-suppressor gene located at 17q21. and 3 of
12 oesophageal adenocarcinomas demonstrate LOH at this site.
Fixe of 20 cases displayed LOH at 17q25-qter (D17S928). but
LOH wxas not detected in the intervening rerion 17q23 (D17S940(.
LOH at 17q25 has been described in breast and oxarian carci-
nomas (Kalikin et al. 1997).
Chromosome 18
The DCC tumour-suppressor cene is most commonlv inactivated
in carcinoma of the colon (Fearon et al. 1990). In our study. LOH
at the DCC locus was detected in 4 of 13 (31%) oesophageal
adenocarcinomas. which is similar to the 29%c detected prexiously
(Huanget al. 1992).
FAL and genomic instability
The median FAL for oesophageal adenocarcinoma was 0.30
(0.06-0.55). This is si2nificantlI hiaher than the FAL of 0.20
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detected for colorectal carcinoma (Vogelstein et al. 1989). head and
neck (FAL of 0.22) (Field et al. 1995) and non-small-cell luna
cancer (FAL of0.09) (Neville et al. 1996). but is similar to a FAL of
0.28 calculated for 20 cases of oesophageal adenocarcinoma
(Barrett et al. 1996a). This higher FAL suggests that a greaterdegree
of genetic abnormality occurs in oesophageal adenocarcinoma than
occurs in colorectal carcinoma. FAL was not significantly related to
survival. grade or TNM classification of the tumours. This is in
agreement with studies of squamous cell carcinoma of the oesoph-
agus (Shibaaaki et al. 1994) and ofosteosarcomas (Yamaguchi et al.
1992). in which the FAL was not related to the clinicopathological
parameters of the tumours. It is probable thaL with respect to the
stage of the tumour and its prognosis. the quantity of the genetic
abnormalities is less important than the actual site of the mutations.
In fact. tumours demonstrating LOH at 9p2 .-3-p21.1 (which span
the sites of the CDKN? tumour-suppressor genes) had a signifi-
cantly greater FAL than those retaining heterozVgyositV at this site. It
is also of note that six of nine patients displaying microsatellite
alterations also demonstrated LOH at the site of the CDKA'N
tumour-suppressor genes. Hence. allelic inactivation at
9p21.3-p21.1 increases the probability of mutations at other sites.
and may be associated w-ith widespread genomic instabilitv.
Similarly. LOH at Sql 1.2-q13.3 (MSH3 mismatch repairgene) was
associated with a hiah FAL. and there was a significant correlation
bet-een LOH on Sq and 9p. LOH at the sites of the CDKN2 and
MSH3 genes tend to occurtogether. and are associated with LOH at
multiple sites. with allelic loss at CDKV2 also beinmc correlated with
microsatellite alterations. Ov-erall. however. the level of microsatel-
lite alterations detected in oesophageal adenocarcinoma was low.
with 39%e of tumours demonstrating alterations and onlv two
tumours demonstrating alterations with more than tmo microsatellite
primers. Other studies have also found low levels of microsatellite
alterations in adenocarcinoma ofthe oesophagus (Keller et al. 1995:
Gleeson et al. 1996) and of the stomach (Dos Santos et al. 1996).
These low levels of microsatellite alterations in adenocarcinoma of
the upper gastrointestinal tract may reflect that the mutator pheno-
type is acquired late in the carcinogenesis sequence.
In conclusion. there are eight chromosomal arms demonstratinc
a si-nificantlv hiah level ofLOH in adenocarcinoma ofthe oesoph-
agus: 3p. 5q. 9p. Ilp. 13q. 17p. 17q and 18q. Significantly hiah
LOH occurred at the sites of the VHL. CDKN2 and TP53 tumour-
suppressor genes. and the site of the MSH3 mismatch repair gene.
A lesser deggree of LOH also occurred at the sites of the APC. Rb
and DCC tumour-suppressor genes. LOH was detected at Ip15.5
and 17q25-qter. and these areas represent putative sites of novel
tumour-suppressor genes. LOH at the sites ofthe CDKN2 and TP53
tumour-suppressor genes occurred in two of three intramucosal
carcinomas studied. and may be useful as biomarkers of earlv
carcinogenesis in patients with Barrett's oesophagus.
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